In a report released today, Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals, with a price target of $10.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Andres Y. Maldonado’s rating is based on Zentalis Pharmaceuticals’ strategic advancements in their Cyclin E1+ platinum-resistant ovarian cancer (PROC) program. The company has initiated DENALI Part 2, a pivotal Phase 2 trial aimed at supporting accelerated approval, with topline data anticipated by the end of 2026. This trial is designed to provide a non-chemotherapy treatment option for a biomarker-defined population that currently lacks approved targeted therapies, positioning azenosertib as a potential best-in-class solution.
Furthermore, Zentalis has demonstrated consistent efficacy across multiple studies, reinforcing Cyclin E1 as a reliable biomarker for predicting azenosertib response. With a cash runway extending into late 2027 and ongoing alignment with the FDA, the company is on a focused regulatory path. These factors, combined with the promising clinical data and strategic execution, underpin Maldonado’s Buy rating and the $10 price target for Zentalis Pharmaceuticals.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $0.00 price target.